Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 16/20 | 0.49 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13523659 | 0.83 | KIF11 (0.51) | KIF11KCNN4 | |
| SCHEMBL1143585 | 0.83 | SMN1; SMN2 (0.48) | KIF11ALDH1A1RXFP1POLB | |
| SCHEMBL10309110 | 0.81 | KIF11 (0.40) | KIF11 | |
| SCHEMBL10315011 | 0.80 | KIF11 (0.49) | KIF11ALDH1A1 | |
| SCHEMBL12347301 | 0.79 | KIF11 (0.53) | KIF11 | |
| SCHEMBL13469291 | 0.79 | KIF11 (0.48) | KIF11ALDH1A1 | |
| SCHEMBL342181 | 0.79 | KIF11 (0.50) | KIF11FFAR1 | |
| SCHEMBL10675433 | 0.79 | KIF11 (0.54) | KIF11 | |
| SCHEMBL18764782 | 0.78 | KIF11 (0.43) | KIF11KCNN4 | |
| SCHEMBL18764783 | 0.78 | KIF11 (0.43) | KIF11KCNN4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230241243-A1 | CARRIER PARTICLE-DRUG CONJUGATES, SELF-IMMOLATIVE LINKERS, AND USES THEREOF | ELUCIDA ONCOLOGY, INC. | 2023-08-03 | — | — | US | disclosed |
| US-20230241243-A1 | CARRIER PARTICLE-DRUG CONJUGATES, SELF-IMMOLATIVE LINKERS, AND USES THEREOF | ELUCIDA ONCOLOGY, INC. | 2023-08-03 | — | — | US | disclosed |
| EP-2258677-B1 | HISTONE DEACETYLASE INHIBITORS | UNIV GEORGETOWN (US) | 2014-06-18 | — | — | EP | disclosed |
| US-8748463-B2 | Histone deacetylase inhibitors and methods of use thereof | GEORGETOWN UNIVERSITY (US) | 2014-06-10 | — | — | US | disclosed |
| US-20130065963-A1 | Histone Deacetylase Inhibitors and Methods of Use Thereof | GEORGETOWN UNIVERSITY (US) | 2013-03-14 | — | — | US | disclosed |
| US-8222451-B2 | Histone deacetylase inhibitors and methods of use thereof | GEORGETOWN UNIVERSITY (US) | 2012-07-17 | — | — | US | disclosed |
| US-8067600-B2 | Histone deacetylase inhibitors and methods of use thereof | GEORGETOWN UNIVERSITY (US) | 2011-11-29 | — | — | US | disclosed |
| US-8067600-B2 | Histone deacetylase inhibitors and methods of use thereof | GEORGETOWN UNIVERSITY (US) | 2011-11-29 | — | — | US | disclosed |
| US-8067600-B2 | Histone deacetylase inhibitors and methods of use thereof | GEORGETOWN UNIVERSITY (US) | 2011-11-29 | — | — | US | disclosed |
| US-20110098504-A1 | Histone Deacetylase Inhibitors and Methods of Use Thereof | GEORGETOWN UNIVERSITY (US) | 2011-04-28 | — | — | US | disclosed |
| US-20050014839-A1 | Histone deacetylase inhibitors and methods of use thereof | GEORGETOWN UNIVERSITY | 2005-01-20 | — | — | US | disclosed |
| US-6307101-B1 | AMIDES SUBSTITUTED WITH MERCAPTOALCOHOL OR MERCAPTOKETONE GROUPS | CAMPBELL DAVID A (US) | 2001-10-23 | — | — | US | disclosed |
| EP-0832100-B1 | NOVEL INHIBITORS OF METALLOPROTEASES AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME | AFFYMAX TECH NV (AN) | 2000-04-05 | — | — | EP | disclosed |
| US-5929278-A | Inhibitors of metalloproteases, pharmaceutical compositions comprising same and methods of their use | AFFYMAX TECHNOLOGIES N.V. (GB) | 1999-07-27 | — | — | US | disclosed |
| US-5840698-A | ENZYME INHIBITORS OF MERCAPTOKETONES AND MERCAPTOALCOHOLS FOR CONTROLLING DISEASES OF TISSUE BREAKDOWN, SKIN DISORDERS, ANTIINFLAMMATORY AGENTS OR ANTITUMOR AGENTS | AFFYMAX TECHNOLOGIES N.V. (GB) | 1998-11-24 | — | — | US | disclosed |
| US-5831004-A | Inhibitors of metalloproteases, pharmaceutical compositions comprising same and methods of their use | AFFYMAX TECHNOLOGIES N.V. (GB) | 1998-11-03 | — | — | US | disclosed |
| EP-0832100-A4 | NOVEL INHIBITORS OF METALLOPROTEASES, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME AND METHODS OF THEIR USE | AFFYMAX TECH NV (AN) | 1998-09-02 | — | — | EP | disclosed |
| EP-0832100-A1 | NOVEL INHIBITORS OF METALLOPROTEASES, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME AND METHODS OF THEIR USE | AFFYMAX TECHNOLOGIES N.V. (AN) | 1998-04-01 | — | — | EP | disclosed |
| WO-1996040204-A1 | NOVEL INHIBITORS OF COLLAGENASE-1 AND STROMELYSIN-I METALLOPROTEASES, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME AND METHODS OF THEIR USE | AFFYMAX TECHNOLOGIES, N.V. (AN) | 1996-12-19 | — | — | WO | disclosed |
| WO-1996040738-A1 | NOVEL INHIBITORS OF METALLOPROTEASES, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME AND METHODS OF THEIR USE | AFFYMAX TECHNOLOGIES, N.V. (AN) | 1996-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130065963-A1 | Histone Deacetylase Inhibitors and Methods of Use Thereof | HDAC5, HDAC6, HDAC1 | KIF11 1307/4885KCNN4 4730/4885HSD17B10 659/4885 |
| US-20110098504-A1 | Histone Deacetylase Inhibitors and Methods of Use Thereof | HDAC5, HDAC6, HDAC1 | KIF11 1307/4885KCNN4 4730/4885HSD17B10 659/4885 |
| US-20230241243-A1 | CARRIER PARTICLE-DRUG CONJUGATES, SELF-IMMOLATIVE LINKERS, AND USES THEREOF | NDC1, KIFC1, SDCBP | KIF11 144/4885KCNN4 4790/4885HSD17B10 2628/4885 |
| US-20050014839-A1 | Histone deacetylase inhibitors and methods of use thereof | HDAC5, HDAC6, HDAC1 | KIF11 1307/4885KCNN4 4730/4885HSD17B10 659/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.